Topics:
Melanoma/Skin Cancer • Medical Oncology
How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?
Does the site of progression or response matter? What if there is progression in the lungs but response in lymphadenopathy, for example?
Answer from: Medical Oncologist at Academic Institution
Good question. This probaby means the patient will not be a long term survivor with targeted agents. The standard thing would be to switch to immunotherapy with either single agent anti PD1 or ipi+nivo combo. A more off base possibility would be to add Pembro to avoid rapid progression upon disconti...
Sign in or Register to read more